ImmunoCellular Therapeutics (IMUC) Ratios
ImmunoCellular Therapeutics Ratios
IMUC's free cash flow for Q4 2022 was $-687.93K. For the 2022 fiscal year, IMUC's free cash flow was increased by $0.00 and operating cash flow was $-687.93K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.08 | 0.34 | 0.07 | 0.21 | 3.58 |
| Quick Ratio | 0.08 | 0.34 | 0.07 | 0.21 | 3.58 |
| Cash Ratio | 0.03 | 0.10 | 0.05 | 0.17 | 3.19 |
| Solvency Ratio | -0.77 | -1.88 | -0.24 | -0.49 | -0.02 |
| Operating Cash Flow Ratio | -1.27 | -2.66 | -0.25 | -0.72 | -4.96 |
| Short-Term Operating Cash Flow Coverage | -3.42 | -6.06 | -0.33 | -0.92 | 0.00 |
| Net Current Asset Value | $ -2.39M | $ -660.98K | $ -5.69M | $ -4.19M | $ -1.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 17.68 | 1.13 | 11.57 | 4.51 | 1.69 |
| Debt-to-Equity Ratio | -0.73 | -0.72 | -0.83 | -0.83 | -1.74 |
| Debt-to-Capital Ratio | -2.77 | -2.51 | -4.95 | -4.81 | 2.35 |
| Long-Term Debt-to-Capital Ratio | -1.23 | 0.00 | -0.07 | -0.17 | 2.35 |
| Financial Leverage Ratio | -0.04 | -0.63 | -0.07 | -0.18 | -1.03 |
| Debt Service Coverage Ratio | -3.44 | -0.66 | -0.17 | -0.72 | -0.00 |
| Interest Coverage Ratio | -19.24 | -2.08 | -3.00 | -13.65 | -308.85 |
| Debt to Market Cap | 0.20 | 0.02 | 0.18 | 0.04 | 0.15 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.05 | 0.03 | 0.06 |
| Net Debt to EBITDA | -0.95 | -0.37 | -4.46 | -1.29 | -1330210.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 93.89% | 100.00% | 100.00% |
| EBT Per EBIT | 105.20% | 94.31% | 103.85% | 91.74% | 102.51% |
| Return on Assets (ROA) | -1933.07% | -485.58% | -393.91% | -344.29% | -160.79% |
| Return on Equity (ROE) | 80.30% | 306.24% | 28.33% | 63.19% | 165.81% |
| Return on Capital Employed (ROCE) | 170.40% | 324.73% | 31.53% | 99.54% | -217.62% |
| Return on Invested Capital (ROIC) | 287.57% | 1140.12% | 183.43% | 5609.73% | -217.62% |
| Return on Tangible Assets | -1933.07% | -485.58% | -393.91% | -344.29% | -160.79% |
| Earnings Yield | -21.41% | -9.74% | -6.14% | -2.85% | -14.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.02 | -0.05 |
| Free Cash Flow Per Share | -0.01 | -0.02 | -0.01 | -0.02 | -0.05 |
| Dividend Paid and CapEx Coverage Ratio | -497969.00 | -535919.00 | -355496.00 | 0.00 | -461277.00 |
| Capital Expenditure Coverage Ratio | -497969.00 | -535919.00 | -355496.00 | 0.00 | -461277.00 |
| Operating Cash Flow Coverage Ratio | -0.85 | -6.06 | -0.30 | -0.76 | -0.82 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -16.63% | -13.79% | -5.41% | -2.83% | -12.09% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.67 | -10.29 | -16.29 | -35.08 | -7.12 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.75 | -31.45 | -4.62 | -22.17 | -11.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.01 | -7.25 | -18.48 | -35.39 | -8.27 |
| Price-to-Operating Cash Flow Ratio | -6.01 | -7.25 | -18.48 | -35.39 | -8.27 |
| Price-to-Earnings Growth (PEG) Ratio | 0.64 | -0.66 | 0.41 | 0.58 | -0.09 |
| Enterprise Value Multiple | -5.86 | -21.28 | -30.76 | -43.36 | -20411584.48 |
| Enterprise Value | 10.71M | 19.77M | 30.74M | 95.70M | 20.41M |
| EV to EBITDA | -5.86 | -21.28 | -30.76 | -43.36 | -20411584.48 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -7.17 | -7.38 | -21.61 | -36.48 | -8.85 |
| EV to Operating Cash Flow | -7.17 | -7.38 | -21.61 | -36.48 | -8.85 |
| Tangible Book Value Per Share | -0.02 | -0.01 | -0.05 | -0.04 | -0.04 |
| Shareholders’ Equity Per Share | -0.02 | -0.01 | -0.05 | -0.04 | -0.04 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.02 | -0.02 | -0.01 | -0.02 | -0.06 |
| Tax Burden | 1.00 | 1.00 | 0.94 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 2.04 | 1.47 | 1.09 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.78 | 1.42 | 0.88 | 0.99 | 0.86 |
Currency in USD